Medical devices, healthcare technology and the business of care
PMA approval · P240044

Globe Pulsed Field System

Kardium, Inc. · Decision date Aug 27, 2025

FDA DECISIONP240044

What did the FDA approve?

FDA records P240044 as an original PMA application. The recorded decision is approval, dated Aug 27, 2025.

FDA approval order statement

approval for the Globe Pulsed Field System. This device is indicated for: The Globe Catheter is indicated for anatomical and electrophysiological mapping and stimulation of cardiac tissue, and for the delivery of ablation energy for the treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, when used in conjunction with the Globe Pulsed Field System. The Globe PF System is indicated for catheter-based cardiac anatomical and electrophysiological mapping and stimulation of cardiac tissue.When used for pulsed field ablation, refer to the Instructions for Use of the compatible cardiac ablation catheter for the specific indications for use.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Aug 27, 2025

FDA source record

Regulatory record facts

Identifier
P240044
Regulatory pathway
Premarket approval application
Applicant
Kardium, Inc.
Product code
QZI
Decision code
APPR
Decision date
Aug 27, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Applicant
Kardium, Inc.
Product code
QZI
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240044 received

    Application receipt date recorded by FDA.

  2. P240044 · FDA decision

    APPR

  3. P240044/S008 · Related supplement

    Globe Pulsed Field System; Globe Catheter

  4. P240044/S007 · Related supplement

    Globe Catheter and Globe Pulsed Field System

Timeline entries are records held by MedtechLedger for P240044. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240044

Product / regulatory recordCompanyPathwayDecision dateSource
Kardium, Inc.PMA supplementOct 23, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Kardium, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
8518 Glenlyon Pkwy., Unit 155, Burnaby, V5J OB6

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records